spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  RAPAMUNE 

 HSMN NewsFeed - 8 Nov 2013
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R) (sirolimus) In Renal Transplant Recipients
Biopharmaceuticals
 HSMN NewsFeed - 31 Jan 2013
Pfizer Wins RAPAMUNE(R) Patent Case in Delaware District Court
Biopharmaceuticals Litigation
 HSMN NewsFeed - 2 Jul 2012
Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2010
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Sep 2010
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Devices Interventional Cardiology
 HSMN NewsFeed - 25 May 2010
NEVO Sirolimus-eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the CYPHER(R) Sirolimus Drug-Eluting Stent over the Endeavor(R) Zotarolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Apr 2009
New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2009
Cordis Celebrates 50 Years of Transforming Cardiovascular Care
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2009
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Mar 2009
CYPHER Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Feb 2009
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved in the European Union for Treatment of Patients With Diabetes
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 4 Sep 2008
Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Aug 2008
The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Aug 2008
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 30 Mar 2008
Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Nov 2007
Pooled Analysis of Long-Term Data Suggests Cypher(R) Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits in Patients with Coronary Artery Disease Compared to Bare Metal Stents
 HSMN NewsFeed - 23 Oct 2007
Adoption of Drug-Eluting Stents Associated with Lower Health Care Costs and Improved Clinical Outcomes
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
New Long-Term Data Suggest Clinical Differences in Safety and Efficacy between CYPHER(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Oct 2007
New Study Shows Excellent Outcomes for CYPHER(R) Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2007
Cordis Corporation Announces Clinical Studies and Events at TCT 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Sep 2007
The CYPHER(R) Sirolimus-Eluting Coronary Stent Outperforms the Taxus Stent in Small Coronary Vessels According to New Clinical Data Analysis Published in the Journal of the American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Sep 2007
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2007
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Aug 2007
Neuromed Appoints Mario Orlando as Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2007
CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Mar 2007
CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Five-Year Randomized Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
CYPHER(R) Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2007
Cordis Corporation to Emphasize Commitment to Interventional Cardiology at ACC.07
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Feb 2007
Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2006
Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 15 Nov 2006
Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER(R) Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Nov 2006
Clinical Studies to be Presented at American Heart Association Scientific Sessions Demonstrate Growing Body of Efficacy and Safety Data for the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Oct 2006
New Randomized Clinical Trial Results Show the Cypher(R) Sirolimus-Eluting Coronary Stent Outperformed the Taxus Stent in Long Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Oct 2006
Biotica Enters into a Research and License Agreement with Wyeth for Novel Rapamycin Analogs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Oct 2006
Data Suggest Different Outcomes Between The CYPHER(R) Sirolimus-Eluting Coronary Stent and the Taxus Stent In 'Real World' Settings and Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2006
Study in New England Journal of Medicine Suggests Heart Attack Patients Fare Better with CYPHER(R) Sirolimus-eluting Coronary Stents Than Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Sep 2006
Data Suggest the Cypher(R) Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Jun 2006
Cordis Corporation's Third-Generation Coronary Stent Approved for Use in Europe
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 May 2006
Cordis Corporation Submits Pre-Market Approval Supplement for Direct Stenting
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 16 May 2006
Study Suggests Drug-Eluting Stent Type and Vessel Size are Important Predictors of Reblockage in Coronary Artery
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2006
Patient Registry to Evaluate Long-Term Safety and Efficacy of Cordis Next Generation Drug-Eluting Coronary Stents in Clinical Practice
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2006
Cordis Corporation Submits Pre-Market Approval Submission for Reblockage in Coronary Stent
Devices Interventional Cardiology FDA
Return to NewsFeed  

 Additional items found! 47

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 47 additional stories matching:
RAPAMUNE
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.